ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
Key Points
Sold entire holding of 109,630 shares; estimated trade value of approximately $2.66 million based on the quarterly average price
Stake was previously 1.2% of fund AUM as of the prior quarter
Post-trade stake: 0 shares, $0 value
- These 10 stocks could mint the next wave of millionaires ›
On October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV disclosed in an SEC filing that it sold out of Pfizer(NYSE:PFE), with an estimated $2.66 million trade.
What happened
According to a Securities and Exchange Commission (SEC) filing dated October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV sold its entire Pfizer position during the third quarter. The fund divested all 109,630 shares, resulting in an estimated $2.66 million in trades based on the average price. The move reduced the fund’s Pfizer holding to zero.
What else to know
The fund fully exited Pfizer, which previously represented 1.2% of its 13F assets; post-trade stake is zero as of September 30, 2025.
Top holdings after the filing:
- NVDA: $47.2 million (19.9% of AUM)
- MSFT: $25.2 million (10.6% of AUM)
- JPM: $13.3 million (5.6% of AUM)
- WMT: $10.27 million (4.3% of AUM)
- RTX: $10.23 million (4.3% of AUM)
As of October 16, 2025, Pfizer shares traded at $24.27, down 8.5% YTD, and underperforming the S&P 500 by 21 percentage points over the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of October 16, 2025) | $24.27 |
| Dividend Yield | 7.05% |
| 1-Year Total Return | -8.5% |
Company snapshot
- Offers a broad portfolio of biopharmaceutical products, including medicines and vaccines for cardiovascular, oncology, immunology, infectious diseases, and rare conditions.
- Generates revenue primarily through the discovery, development, manufacturing, and global distribution of branded pharmaceuticals and vaccines.
- Serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and disease control and prevention centers worldwide.
- Pfizer is a leading global biopharmaceutical company with a diversified product lineup across multiple therapeutic areas. The company maintains a competitive edge through its scale, established brands, and broad international reach.
Foolish take
ASSET PLANNING SERVICES INC /LA/ /ADV recently sold off its entire $2.66 million stake in Pfizer. This comes after a tough year for the pharmaceutical giant, with shares down over 8% year-to-date and significantly underperforming the S&P 500. This exit might signal a broader shift by investors looking for stronger growth or more reliable momentum elsewhere in the market. Pfizer is still dealing with challenges from the post-pandemic era, including a drop in COVID-related revenues and intense competition in its vaccine and therapeutic areas.
The fund’s portfolio is now heavily focused on tech and financial leaders like NVIDIA, Microsoft, and JPMorgan Chase. This suggests a growing confidence in innovation and capital markets over traditional healthcare companies. However, with Pfizer maintaining a strong drug pipeline and a consistent dividend yield, long-term investors might see the current weakness as an opportunity rather than a reason to move on.
Glossary
13F reportable assets: Assets that institutional investment managers must disclose quarterly to the SEC, showing holdings in U.S. publicly traded securities.
Assets under management (AUM): The total market value of investments managed by a fund or investment firm on behalf of clients.
Fully exited: When an investor sells all shares of a particular holding, reducing its position to zero.
Divested: The act of selling off an asset or investment, often to reduce exposure or reallocate capital.
Stake: The proportion or percentage of ownership an investor holds in a company or fund.
Quarterly average price: The average price of a security over a specific quarter, used to estimate trade values.
Dividend yield: A financial ratio showing how much a company pays in dividends each year relative to its share price.
Biopharmaceutical: Refers to drugs and therapies produced using biotechnology, often involving living organisms or biological systems.
Therapeutic areas: Categories of diseases or conditions that a pharmaceutical company targets with its products.
Wholesalers: Companies that buy large quantities of products from manufacturers to sell in smaller amounts to retailers or other buyers.
TTM: The 12-month period ending with the most recent quarterly report.
Fund: An investment vehicle pooling money from multiple investors to buy securities according to a stated strategy.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,052%* — a market-crushing outperformance compared to 190% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of October 13, 2025
JPMorgan Chase is an advertising partner of Motley Fool Money. Adam Palasciano has positions in JPMorgan Chase, but not in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase, Microsoft, Nvidia, Pfizer, and Walmart. The Motley Fool has a disclosure policy.
Recommended Articles
